Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
Neuroendocrine tumors (NETs) are associated with variable prognosis, with grade 1 and 2 NETs having more favorable outcomes than grade 3. Patients with gastroenteropancreatic (GEP)-NET need individualized interdisciplinary evaluations and treatment. New treatment options have become available with significant improvements in progression-free survival. Peptide receptor radionuclide therapy (PRRT) using (90)Y or (177)Lu-labeled somatostatin analogues (SSTa) has also shown promise in the treatment of advanced progressive NETs. (68)Ga-1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA)-SSTa can be used as companion imaging agents to assist in radionuclide therapy selection. (68)Ga-DOTA-SSTa PET/computed tomography might also provide information for prognosis, tumor response assessment to PRRT, and internal dosimetry.
['Taïeb|David|D|', 'Garrigue|Philippe|P|', 'Bardiès|Manuel|M|', 'Abdullah|Ahmad Esmaeel|AE|', 'Pacak|Karel|K|']
D014408:Biomarkers, Tumor D004067:Digestive System Neoplasms D005710:Gallium Radioisotopes D006801:Humans D007553:Isotope Labeling D064847:Multimodal Imaging D018358:Neuroendocrine Tumors D049268:Positron-Emission Tomography D011379:Prognosis D011874:Radiometry D019275:Radiopharmaceuticals D061089:Radiotherapy, Image-Guided D017481:Receptors, Somatostatin D013004:Somatostatin D014057:Tomography, X-Ray Computed D016896:Treatment Outcome
Somatostatin Gastroenteropancreatic Neuroendocrine PET Gallium radioisotopes